FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:190-192 January 10, 2008 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Bissler, J. J. PubMed Citation

Owing to their immunosuppressive and antiproliferative effects, sirolimus (also called rapamycin) and related drugs are being evaluated as part of many transplant immunosuppresion regimens, as well as for a plethora of medical conditions such as type 1 diabetes, macular degeneration, coronary artery disease, and metastatic or refractory cancers of the breast, prostate, lung, and liver, to name but a few.

The effects of sirolimus are mediated by its inhibition of the curiously named cytoplasmic protein mammalian target of rapamycin (mTOR), a ubiquitous serine–threonine kinase that is intimately involved in the regulation of protein synthesis, cell growth, cytoskeletal organization, and other . . . [Full Text of this Article]

Source Information

From the Division of Pediatric Nephrology (E.P.) and the Departments of Neurology and Pediatrics (E.T.), Massachusetts General Hospital, Boston.

This article has been cited by other articles:

• Egan, J. J., Remund, K. F., Corris, P., Bissler, J. J., Young, L. R., McCormack, F. X. (2008). Sirolimus for Lymphangioleiomyomatosis Lesions. NEJM 358: 1963-1964 [Full Text]